Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-002177-25
    Sponsor's Protocol Code Number:19-255-03
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2021-09-02
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2021-002177-25
    A.3Full title of the trial
    A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 in Combination with Cetuximab as a Salvage Regimen for Solid Tumors
    STUDIO DI FASE 1B/2, IN APERTO, MULTICENTRICO, DI INCREMENTO DELLA DOSE E DI ESPANSIONE DELLA DOSE SU NKTR-255 IN COMBINAZIONE CON CETUXIMAB COME REGIME DI SALVATAGGIO PER I TUMORI SOLIDI
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study on NKTR-255 in combination with Cetuximab as salvage treatment for Solid Tumors
    Uno studio su NKTF-255 in combinazione con Cetuximab come trattamento di salvataggio per i tumori solidi
    A.3.2Name or abbreviated title of the trial where available
    NA
    NA
    A.4.1Sponsor's protocol code number19-255-03
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT04616196
    A.5.4Other Identifiers
    Name:NANumber:NA
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNEKTAR THERAPEUTICS
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNektar Therapeutics
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPPD
    B.5.2Functional name of contact pointProject Manager
    B.5.3 Address:
    B.5.3.1Street Address3900 Paramount Parkway
    B.5.3.2Town/ cityMorrisville
    B.5.3.3Post codeNC 27560
    B.5.3.4CountryUnited States
    B.5.4Telephone number+19105582918
    B.5.5Fax number+19105582918
    B.5.6E-maileboni.oputa@ppdi.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Erbitux
    D.2.1.1.2Name of the Marketing Authorisation holderMerck Europe B.V.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namecetuximab
    D.3.2Product code [NA]
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCETUXIMAB
    D.3.9.1CAS number 2361317-09-9
    D.3.9.2Current sponsor codeNA
    D.3.9.4EV Substance CodeSUB01178MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.1.1.1Trade name NKTR-255
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNKTR-255
    D.3.2Product code [NKTR-255]
    D.3.4Pharmaceutical form Lyophilisate for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNKTR-255
    D.3.9.1CAS number 2361317-09-9
    D.3.9.2Current sponsor codeNKTR-255
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Relapsed or refractory (R/R) head and neck squamous cell carcinoma (HNSCC) or colorectal carcinoma (CRC)
    Carcinoma a cellule squamose della testa e del collo (HNSCC) o carcinoma del colon-retto (CRC) recidivante o refrattario (R/R
    E.1.1.1Medical condition in easily understood language
    Head and neck squamous cell cancer or colorectal cancer which has spread to other part of body
    Cancro a cellule squamose della testa e del collo o carcinoma del colon-retto che si e' diffuso in altre parti del corpo
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 22.0
    E.1.2Level LLT
    E.1.2Classification code 10082179
    E.1.2Term Squamous cell carcinoma of head and neck metastatic
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10009963
    E.1.2Term Colon carcinoma recurrent
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10007336
    E.1.2Term Carcinoma colon recurrent
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level PT
    E.1.2Classification code 10060121
    E.1.2Term Squamous cell carcinoma of head and neck
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Phase 1b (Dose Escalation):
    • To evaluate the safety, tolerability, and define the maximum tolerated dose (MTD), and/or RP2D of NKTR-255 in combination with cetuximab in R/R metastatic HNSCC or CRC.
    Phase 2 (Dose Expansion):
    • To evaluate the safety and tolerability of NKTR-255 in patients with R/R metastatic HNSCC or CRC.
    • To evaluate the efficacy of NKTR-255 in combination with cetuximab in R/R metastatic HNSCC or CRC by assessing the objective response rate (ORR) by RECIST 1.1.
    Fase 1b (Incremento della dose):
    • Valutare la sicurezza, la tollerabilità e definire la dose massima tollerata (MTD) e/o la RP2D di NKTR-255 in combinazione con cetuximab nel HNSCC o CRC metastatico R/R.
    Fase 2 (Espansione della dose):
    • Valutare la sicurezza e la tollerabilità di NKTR-255 in pazienti con HNSCC o CRC metastatico R/R.
    • Valutare l'efficacia di NKTR-255 in combinazione con cetuximab nel HNSCC o CRC metastatico R/R valutando il tasso di risposta obiettiva (ORR) secondo RECIST 1.1.
    E.2.2Secondary objectives of the trial
    • To evaluate the anti-tumor activity of the combination of NKTR-255 and cetuximab by assessing progression-free survival(PFS) and overall survival (OS).
    • To characterize the pharmacodynamic (PD) effects and change from baseline in immune cell populations (natural killer [NK], CD8+ cells, and other immune populations), tumor cells, cytokine levels, and changes in gene expression after administration of NKTR-255 in combination with cetuximab.
    • To characterize the pharmacokinetics (PK) of NKTR-255 and cetuximab.
    • To assess development of anti-drug antibodies against NKTR-255.
    • Valutare l'attività antitumorale della combinazione di NKTR-255 e cetuximab valutando la sopravvivenza libera da progressione (PFS) e la sopravvivenza globale (OS).
    • Caratterizzare gli effetti farmacodinamici (PD) e la variazione dalla baseline a livello di popolazioni di cellule immunitarie (natural killer [NK], cellule CD8+ e altre popolazioni immunitarie), cellule tumorali, livelli di citochine e variazioni nell'espressione genica dopo la somministrazione di NKTR-255 in combinazione con cetuximab.
    • Caratterizzare la farmacocinetica (PK) di NKTR-255 e cetuximab.
    • Valutare lo sviluppo di anticorpi anti-farmaco contro NKTR-255.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Inclusion Criteria for All Patients
    1. Patients must be at least 18 years of age at study entry
    2. Patients must be capable of understanding and providing a written informed consent.
    3. Women of childbearing potential (WCBP) must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) at Screening and a negative serum or urine pregnancy test within 24 hours prior to dosing. Women of childbearing potential and men who are sexually active with women of childbearing potential must commit to use contraception.
    4. Histologically confirmed diagnosis of a locally advanced (not amenable to curative therapy such as surgical resection) or metastatic cancer of the following histologies: HNSCC or CRC
    5. Patients who have previously received cetuximab or other EGFR directed therapies are excluded from Phase 2 of the trial, unless cetuximab was given as part of a primary treatment approach, with no progressive disease for at least 4 months following the end of prior cetuximab treatment.
    6. Life expectancy > 12 weeks as determined by the Investigator
    7. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
    8. Measurable disease per RECIST 1.1
    9. Patients must have demonstrated adequate organ function during Screening:
    a. Estimated glomerular filtration rate = 40 mL/min/1.73m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation
    Inclusion Criteria for Specific Tumor Types
    • Head and Neck Cancer
    1. Patients must have histologically or cytologically confirmed advanced, recurrent, or metastatic HNSCC that could not be treated with curative intent. "Advanced" is defined as either locally advanced HNSCC not amenable to curative surgery or radiotherapy or with distant metastases.
    2. Progression (or toxicity precluding additional treatment) on any first or second line platinum-based chemotherapy and/or anti-PD-1 or programmed death-ligand 1 (anti-PD-L1) (together termed "anti-PD-(L)1") antibody
    3. Patients who have undergone treatment with anti-PD-(L)1 antibody must have had the last dose of antibody at least 4 weeks prior and evidence of tumor progression before they can be enrolled into this study.
    4. Ineligible for platinum-based (either cisplatin or carboplatin) chemotherapy or chemoradiation due to decline in renal function and/or patient's intolerance
    5. Must have known status by pathology for human papillomavirus (HPV) and Epstein-Barr virus (EBV) in HNSCC, either metastatic or recurrent disease.
    • Colorectal Cancer
    1. Patients must have a histologically or cytologically confirmed diagnosis of advanced CRC; patients in Phase 2 must have confirmed KRAS wild type EGFR-expressing advanced CRC. "Advanced" is defined as either locally advanced unresectable cancer or metastatic disease.
    2. Patients must have received or were intolerant to at least 2 prior cancer therapy regimens administered for metastatic disease.
    3. Patients with high microsatellite instability (MSI-H) or mismatched repair disease (dMMR) tumors must have been exposed to checkpoint inhibitors such as anti-PD-(L)1 or anticytotoxic T-lymphocyte-associated protein (CTLA)-4 antibody.
    Criteri di inclusione per tutti i pazienti:
    1. I pazienti devono avere almeno 18 anni di età al momento dell'ingresso nello studio
    2. I pazienti devono essere in grado di comprendere e fornire un consenso informato scritto.
    3. Le donne in età fertile (WCBP) devono avere un test di gravidanza sierico negativo (sensibilità minima 25 IU/L o unità equivalenti di gonadotropina corionica umana [HCG]) allo Screening e un test di gravidanza su siero o urina negativo nelle 24 ore prima della somministrazione . Le donne in età fertile e gli uomini sessualmente attivi con donne in età fertile devono impegnarsi a utilizzare la contraccezione
    4. Diagnosi istologicamente confermata di un tumore localmente avanzato (non suscettibile di terapia curativa come la resezione chirurgica) o metastatico delle seguenti istologie: HNSCC o CRC
    5. I pazienti che hanno precedentemente ricevuto cetuximab o altre terapie mirate all'EGFR sono esclusi dalla Fase 2 dello studio, a meno che il cetuximab non sia stato somministrato come parte di un approccio terapeutico primario, senza malattia progressiva per almeno 4 mesi dopo la fine del precedente trattamento con cetuximab.
    6. Aspettativa di vita > 12 settimane come determinato dallo sperimentatore
    7. Performance status 0 o 1 dell'Eastern Cooperative Oncology Group (ECOG)
    8. Malattia misurabile secondo RECIST 1.1
    9. I pazienti devono aver dimostrato un'adeguata funzionalità degli organi durante lo screening:
    a. Velocità di filtrazione glomerulare stimata = 40 mL/min/1,73 m2 calcolata utilizzando l'equazione della creatinina della Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
    Criteri di inclusione per specifici tipi di tumore • Cancro alla testa e al collo
    1. I pazienti devono avere un HNSCC avanzato, ricorrente o metastatico confermato istologicamente o citologicamente che non può essere trattato con intento curativo. "Avanzato" è definito come HNSCC localmente avanzato non suscettibile di chirurgia curativa o radioterapia o con metastasi a distanza.
    2. Progressione (o tossicità che preclude un trattamento aggiuntivo) su qualsiasi chemioterapia di prima o seconda linea a base di platino e/o anti-PD-1 o ligando di morte programmata 1 (anti-PD-L1) (collettivamente denominati "anti-PD-( L)1") anticorpo
    3. I pazienti che sono stati sottoposti a trattamento con l'anticorpo anti-PD-(L)1 devono aver ricevuto l'ultima dose di anticorpi almeno 4 settimane prima e l'evidenza di progressione del tumore prima di poter essere arruolati in questo studio.
    4. Non idonei alla chemioterapia o alla chemioradioterapia a base di platino (cisplatino o carboplatino) a causa del declino della funzionalità renale e/o dell'intolleranza del paziente
    5. Deve avere lo stato noto per patologia del virus del papilloma umano (HPV) e del virus di Epstein-Barr (EBV) nell'HNSCC, malattia metastatica o ricorrente.
    • Cancro colorettale
    1. I pazienti devono avere una diagnosi confermata istologicamente o citologicamente di CRC avanzato; i pazienti in fase 2 devono avere CRC avanzato che esprime EGFR KRAS wild type confermato.
    "Avanzato" è definito come cancro non resecabile localmente avanzato o malattia metastatica.
    2. I pazienti devono aver ricevuto o essere stati intolleranti ad almeno 2 precedenti regimi di terapia del cancro somministrati per la malattia metastatica.
    3. I pazienti con tumori con elevata instabilità dei microsatelliti (MSI-H) o malattia di riparazione non corrispondente (dMMR) devono essere stati esposti a inibitori del checkpoint come l'anti-PD-(L)1 o la proteina associata ai linfociti T (CTLA)-4 anticitotossica anticorpo
    E.4Principal exclusion criteria
    1.Use of an IMP or an investigational device within 28 days before administration of first dose of study drug(s)
    2.Active, known, or suspected autoimmune disease. Patients requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease that requires systemic corticosteroids or immunosuppressive.
    3.History of allergy or known hypersensitivity to murine protein or study drug components
    4.History of organ transplant that requires ongoing use of immunosuppressive agents
    5.Patients who have been previously treated with IL-2 or IL-15
    6.Patients with HNSCC who require treatment with anticoagulation therapy are not eligible.
    7.Contraindication to or unable to receive cetuximab
    8.Patient has had prior Grade 4 IRR to cetuximab
    9.Unresolved toxicity from previous anti-cancer therapy, unless resolved to Grade = 1; or resolved to Grade 2; or resulting from incomplete recovery from surgery
    10.Prior surgery or radiotherapy within 14 days of initiating study drug(s). Patients must have recovered from all radiation-related toxicities.
    11.Patients participating in observational studies should be discussed with the Medical Monitor to confirm eligibility.
    12.Patients who have had < 28 days since the last anti-cancer treatment, chemotherapy or biological therapy, or < 14 days from approved tyrosine kinase inhibitor therapy, or systemic or inhaled steroid therapy at doses greater than 10 mg of prednisone or equivalent before administration of the first dose of study drug(s).
    13.Patients who have received systemic interferon alpha within the previous 6 months prior to enrollment in the study are not eligible.
    14.Active infection requiring systemic therapy within 7 days prior to dosing
    15.Evidence of clinically significant interstitial lung disease or active, noninfectious pneumonitis
    16.Known immunodeficiency or active human immunodeficiency virus
    (HIV)
    17.Known to be seropositive or active for hepatitis B or hepatitis C
    18.QTcF> 450 ms for men and > 470 ms for women at Screening
    19. History of unstable or deteriorating cardiac disease within the previous 6 months prior to Screening
    20.Has a known additional malignancy that is progressing or requires active treatment, exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer.
    21.Patient has any of the following laboratory test results during Screening:
    a.AST and ALT level = 2.5 times ULN;
    b.Alkaline phosphatase level = 2.5 × ULN;
    d.Potassium level < 3.0 mEq/L; or
    e.Corrected serum calcium > 14.0 mg/dL (3.5 mmol/L)
    22.Patient is a woman who is pregnant or breastfeeding or planning to become pregnant while enrolled in this study or within 4 weeks after the last dose of NKTR-255 or within 2 months after the last dose of cetuximab.
    23.Active brain metastases or leptomeningeal metastases patients with brain metastases are eligible if these have been treated and there is no radiographic evidence of progression for at least 4 weeks after treatment is complete. There must also be no requirement for immunosuppressive doses of systemic corticosteroids for at least 4 weeks prior to study treatment. Stable dose of anticonvulsants is required within 14 days prior to study treatment. Treatment for central nervous system metastases may include stereotactic radiosurgery or neurosurgical resection. Patients who received whole brain radiation therapy are not eligible.
    1. Uso di un IMP o di un dispositivo sperimentale entro 28 giorni prima della somministrazione della prima dose del/i farmaco/i in studio
    2. Malattia autoimmune attiva, nota o sospetta. Pazienti che richiedono un trattamento sistemico negli ultimi 3 mesi o una storia documentata di malattia autoimmune clinicamente grave che richiede corticosteroidi sistemici o immunosoppressori.
    3. Storia di allergia o ipersensibilità nota alle proteine ¿¿murine o ai componenti del farmaco in studio
    4. Storia di trapianti di organi che richiedono l'uso continuo di agenti immunosoppressivi
    5.Pazienti che sono stati precedentemente trattati con IL-2 o IL-15
    6. I pazienti con HNSCC che richiedono un trattamento con terapia anticoagulante non sono eleggibili.
    7. Controindicazione o impossibilità di ricevere cetuximab
    8. Il paziente ha avuto una precedente IRR di grado 4 a cetuximab
    9. Tossicità non risolta da precedente terapia antitumorale, a meno che non sia risolta a Grado = 1; o risolto al Grado 2; o derivanti da un recupero incompleto da un intervento chirurgico
    10.Precedente intervento chirurgico o radioterapia entro 14 giorni dall'inizio del/i farmaco/i in studio. I pazienti devono essersi ripresi da tutte le tossicità correlate alle radiazioni.
    11. I pazienti che partecipano a studi osservazionali devono essere discussi con il Medical Monitor per confermare l'idoneità.
    12.Pazienti che hanno avuto < 28 giorni dall'ultimo trattamento antitumorale, chemioterapia o terapia biologica, o < 14 giorni dalla terapia approvata con inibitori della tirosin-chinasi, o terapia steroidea sistemica o per via inalatoria a dosi superiori a 10 mg di prednisone o equivalente prima somministrazione della prima dose del/i farmaco/i in studio13. I pazienti che hanno ricevuto interferone alfa sistemico nei 6 mesi precedenti l'arruolamento nello studio non sono ammissibili.
    14.Infezione attiva che richiede terapia sistemica entro 7 giorni prima della somministrazione
    15.Evidenza di malattia polmonare interstiziale clinicamente significativa o polmonite attiva non infettiva
    16.Immunodeficienza nota o virus dell'immunodeficienza umana attivo (HIV)
    17. Noto per essere sieropositivo o attivo per l'epatite B o l'epatite C 18.QTcF > 450 ms per gli uomini e > 470 ms per le donne allo Screening
    19. Storia di malattia cardiaca instabile o in peggioramento nei 6 mesi precedenti lo screening
    20. Ha un tumore maligno aggiuntivo noto che sta progredendo o richiede un trattamento attivo, le eccezioni includono il carcinoma a cellule basali della pelle, il carcinoma a cellule squamose della pelle che è stato sottoposto a terapia potenzialmente curativa o il cancro della cervice uterina in situ.
    21. Il paziente presenta uno dei seguenti risultati dei test di laboratorio durante lo screening: a.livello AST e ALT = 2,5 volte ULN; b.Livello di fosfatasi alcalina = 2,5 × ULN; c.Livello totale di bilirubina = 2 × ULN; e. Calcio sierico corretto > 14,0 mg/dL (3,5 mmol/L)
    22.Il paziente è una donna in gravidanza o allattamento o che sta pianificando una gravidanza mentre è arruolata in questo studio o entro 4 settimane dall'ultima dose di NKTR-255 o entro 2 mesi dall'ultima dose di cetuximab.
    23.Pazienti con metastasi cerebrali attive o metastasi leptomeningee sono eleggibili se queste sono state trattate e non vi è evidenza radiografica di progressione per almeno 4 settimane dopo il completamento del trattamento. Inoltre, non devono essere richieste dosi immunosoppressive di corticosteroidi sistemici per almeno 4 settimane prima del trattamento in studio. È richiesta una dose stabile di anticonvulsivanti entro 14 giorni prima del trattamento in studio. Il trattamento per le metastasi del sistema nervoso centrale può includere la radiochirurgia stereotassica o la resezione neurochirurgica. I pazienti che hanno ricevuto la radioterapia dell'intero cervello non sono eleggibili
    E.5 End points
    E.5.1Primary end point(s)
    1. Incidence of Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE) of NKTR-255 with Cetuximab:
    Safety and tolerability of NKTR-255 in combination with cetuximab as evaluated by dose limiting toxicities, incidence of drug-related Adverse Events (AEs), SAEs, and AEs leading to discontinuation, deaths, and clinical laboratory abnormalities per CTCAE 5.0
    2.Efficacy of NKTR-255 with Cetuximab:
    Efficacy of NKTR-255 in combination with cetuximab in R/R metastatic HNSCC or CRC by assessing the objective response rate (ORR) by RECIST 1.1
    1.Incidenza di Eventi Avversi Emergenti del Trattamento (TEAE) ed Eventi Avversi Seri (SAE) di NKTR-255 con Cetuximab:
    Sicurezza e tollerabilita' di NKTR-255 in comninazione con cetuximab come valutata da dose limitante di tossicita', incidenza di Eventi Avversi (AEs) correlati al farmaco, SAEs e AEs che portano ad interruzioni, decessi e anomalie di laboratorio clinico per CTCAE 5.0
    2. Efficacia di NKTR-255 con Cetuximab
    Efficacia di NKTR-255 in combinazione con cetuximab in R/R metastatico HNSCC o CRC valutando il tasso di risposta obiettiva (ORR) da RECIST 1:1
    E.5.1.1Timepoint(s) of evaluation of this end point
    1. Safety and tolerability: throughout the trial till 60 days after the last dose of study treatment
    2. Efficacy: Through study completion, an expected average of 1 year
    1. Sicurezza e tollerabilita' durante lo studio fino a 60 giorni dopo l'ultima dose del trattamento dello studio
    2.Efficacia. Al completamento dello studio, una media prevista di 1 anno
    E.5.2Secondary end point(s)
    Efficacy of NKTR-255 with Cetuximab:
    Evaluate the anti-tumor activity of the combination of NKTR-255 and cetuximab by assessing progression-free survival (PFS) and overall survival (OS).
    Efficacia di NKTR-255 con Cetuximab
    Valutare l'attivita' anti-tumorale della combinazione di NKTR-255 e cetuximab considerando la sopravvivenza libera da progressione (PFS) e la sopravvivenza globale (OS).
    E.5.2.1Timepoint(s) of evaluation of this end point
    Through study completion, an expected average of 1 year
    Al completamento dello studio, una media prevista di un 1 anno
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    1b
    1b
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Dose di incremento e dose di espansione
    DOSE ESCALATION AND DOSE EXPANSION
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA8
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United States
    France
    Italy
    Spain
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of study is defined as no more than 2 years after the last patient received his or her last dose of NKTR-255 or Sponsor decision to terminate the study, whichever comes first
    La fine dello studio e' definita come non piu' di 2 anni dopo che l'utimo paziente ha ricevuto l'ultima dose di NKTR-255 o per decisione dello Sponsor di terminare lo studio a seconda di quale evento si verifichi per primo
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 51
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 27
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state3
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 12
    F.4.2.2In the whole clinical trial 78
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    none
    nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-11-29
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-07-13
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 12:30:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA